R

RenovoRx
D

RNXT

1.34000
USD
0.12
(9.84%)
Market Closed
Volume
49
EPS
-0
Div Yield
-
P/E
-2
Market Cap
32,161,794
News

Title: RenovoRx

Sector: Healthcare
Industry: Biotechnology
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.